These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 11981373)

  • 1. Immune reconstitution after successful treatment with protease inhibitor-based and protease inhibitor-sparing antiretroviral regimens.
    Smith KY; Steffens CM; Truckenbrod A; Landay A; Al-Harthi L
    J Acquir Immune Defic Syndr; 2002 Apr; 29(5):544-5. PubMed ID: 11981373
    [No Abstract]   [Full Text] [Related]  

  • 2. Three-year immune reconstitution in PI-sparing and PI-containing antiretroviral regimens in advanced HIV-1 disease.
    Samri A; Goodall R; Burton C; Imami N; Pantaleo G; Kelleher A; Poli G; Gotch F; Autran B
    Antivir Ther; 2007; 12(4):553-8. PubMed ID: 17668564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease.
    Autran B; Carcelain G; Li TS; Blanc C; Mathez D; Tubiana R; Katlama C; Debré P; Leibowitch J
    Science; 1997 Jul; 277(5322):112-6. PubMed ID: 9204894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunologic effects of combined protease inhibitor and reverse transcriptase inhibitor therapy in previously treated chronic HIV-1 infection.
    Giorgi JV; Majchrowicz MA; Johnson TD; Hultin P; Matud J; Detels R
    AIDS; 1998 Oct; 12(14):1833-44. PubMed ID: 9792384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in cellular activation and apoptosis in HIV-infected patients receiving protease inhibitors or nonnucleoside reverse transcriptase inhibitors.
    Benito JM; López M; Martín JC; Lozano S; Martínez P; González-Lahoz J; Soriano V
    AIDS Res Hum Retroviruses; 2002 Dec; 18(18):1379-88. PubMed ID: 12487809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy.
    García F; Plana M; Vidal C; Cruceta A; O'Brien WA; Pantaleo G; Pumarola T; Gallart T; Miró JM; Gatell JM
    AIDS; 1999 Jul; 13(11):F79-86. PubMed ID: 10449278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunologic reconstitution after 1 year of highly active antiretroviral therapy, with or without protease inhibitors.
    Plana M; Martínez C; García F; Maleno MJ; Barceló JJ; García A; Lejeune M; Vidal C; Cruceta A; Miró JM; Pumarola T; Gallart T; Gatell JM
    J Acquir Immune Defic Syndr; 2002 Apr; 29(5):429-34. PubMed ID: 11981357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in CD4+ and CD8+ T cell subsets in response to highly active antiretroviral therapy in HIV type 1-infected patients with prior protease inhibitor experience.
    Gray CM; Schapiro JM; Winters MA; Merigan TC
    AIDS Res Hum Retroviruses; 1998 May; 14(7):561-9. PubMed ID: 9591710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD4+CD7-lymphocyte subset is expanded in HIV-infected patients with low CD4 cell count rescue during highly active antiretroviral therapy.
    Meroni L; Varchetta S; Manganaro D; Moscatelli G; Moroni M; Galli M
    AIDS; 1999 Apr; 13(5):621-2. PubMed ID: 10203388
    [No Abstract]   [Full Text] [Related]  

  • 10. [Antiretroviral therapy in patients infected with HIV-1].
    Corti ME
    Medicina (B Aires); 1998; 58 Suppl 1():49-56. PubMed ID: 9674248
    [No Abstract]   [Full Text] [Related]  

  • 11. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315.
    Lederman MM; Connick E; Landay A; Kuritzkes DR; Spritzler J; St Clair M; Kotzin BL; Fox L; Chiozzi MH; Leonard JM; Rousseau F; Wade M; Roe JD; Martinez A; Kessler H
    J Infect Dis; 1998 Jul; 178(1):70-9. PubMed ID: 9652425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Highly active antiretroviral therapy results in a decrease in CD8+ T cell activation and preferential reconstitution of the peripheral CD4+ T cell population with memory rather than naive cells.
    Evans TG; Bonnez W; Soucier HR; Fitzgerald T; Gibbons DC; Reichman RC
    Antiviral Res; 1998 Oct; 39(3):163-73. PubMed ID: 9833957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunological benefits of antiretroviral therapy in very early stages of asymptomatic chronic HIV-1 infection.
    Plana M; García F; Gallart T; Tortajada C; Soriano A; Palou E; Maleno MJ; Barceló JJ; Vidal C; Cruceta A; Miró JM; Gatell JM
    AIDS; 2000 Sep; 14(13):1921-33. PubMed ID: 10997396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccination and HIV-1 replication during highly active antiretroviral therapy.
    Kroon FP; Beersma MF; Kroes AC; Groeneveld PH; van Dissel JT
    AIDS; 1999 Jan; 13(1):135-6. PubMed ID: 10207556
    [No Abstract]   [Full Text] [Related]  

  • 15. Long-term evaluation of T-cell subsets and T-cell function after HAART in advanced stage HIV-1 disease.
    Mezzaroma I; Carlesimo M; Pinter E; Alario C; Sacco G; Muratori DS; Bernardi ML; Paganelli R; Aiuti F
    AIDS; 1999 Jul; 13(10):1187-93. PubMed ID: 10416521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of response (CD4 cell count and viral load) at 6 months in HIV-infected patients on highly active antiretroviral therapy.
    Barreiro PM; Dona MC; Castilla J; Soriano V
    AIDS; 1999 Mar; 13(4):525-6. PubMed ID: 10197384
    [No Abstract]   [Full Text] [Related]  

  • 17. Functional restoration of human immunodeficiency virus and Epstein-Barr virus-specific CD8(+) T cells during highly active antiretroviral therapy is associated with an increase in CD4(+) T cells.
    Kostense S; Otto SA; Knol GJ; Manting EH; Nanlohy NM; Jansen C; Lange JM; van Oers MH; Miedema F; van Baarle D
    Eur J Immunol; 2002 Apr; 32(4):1080-9. PubMed ID: 11920575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Normalization of CD4+ cell numbers and reduced levels of memory CD8+ cells in blood and tonsillar tissue after highly active antiretroviral therapy in early HIV type-1 infection.
    Dyrhol-Riise AM; Voltersvik P; Røsok BI; Olofsson J; Asjö B
    AIDS Res Hum Retroviruses; 2000 Feb; 16(3):191-201. PubMed ID: 10710207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction of viral load and immune complex load on CD4+ lymphocytes as a consequence of highly active antiretroviral treatment (HAART) in HIV-infected hemophilia patients.
    Daniel V; Süsal C; Melk A; Weimer R; Kröpelin M; Zimmermann R; Huth-Kühne A; Uhle C; Opelz G
    Immunol Lett; 1999 Aug; 69(2):283-9. PubMed ID: 10482364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequency of cytokine-producing T cells in HIV-infected patients treated with stavudine, didanosine, and ritonavir.
    Levacher M; Bouscarat F; Landman R; Chau F; Damond F; Gaudebout C; Mathez D; Leibowitch J; Saimot AG; Sinet M
    AIDS Res Hum Retroviruses; 2000 Nov; 16(17):1869-75. PubMed ID: 11118072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.